The Surveillance After Extremity Tumor Surgery (SAFETY) trial: protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial

被引:17
作者
Ghert, Michelle [1 ]
Bhandari, Mohit [1 ,3 ]
Bozzo, Anthony [1 ]
Dijkstra, P. D. Sander [4 ]
Griffin, Anthony [5 ]
Grimer, Robert [6 ]
Hayden, James [7 ]
Manherz, Arlene [1 ]
Masrouha, Karim [1 ]
McKay, Paula [1 ]
Miller, Benjamin [8 ]
Parasu, Naveen [9 ]
Puri, Ajay [10 ]
Randall, R. Lor [11 ]
Schneider, Patricia [1 ]
Sprague, Sheila [1 ]
Szpakowski, Nina [3 ]
Thabane, Lehana [3 ]
Turcotte, Robert [12 ]
Velez, Roberto [13 ]
Wilson, David [1 ]
Zbuk, Kevin [14 ]
Guyatt, Gordon [3 ,15 ]
机构
[1] McMaster Univ, Dept Surg, Hamilton, ON, Canada
[2] Hamilton Hlth Sci, Juravinski Canc Ctr, Hamilton, ON, Canada
[3] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[4] Leiden Univ, Med Ctr, Dept Orthopaed, Leiden, Netherlands
[5] Mt Sinai Hosp, Musculoskeletal Oncol Unit, Toronto, ON, Canada
[6] Univ Birmingham, Dept Surg, Birmingham, W Midlands, England
[7] Oregon Hlth & Sci Univ, Dept Orthopaed & Rehabil, Portland, OR 97201 USA
[8] Univ Iowa, Dept Orthopaed & Rehabil, Iowa City, IA USA
[9] McMaster Univ, Dept Radiol, Hamilton, ON, Canada
[10] Tata Mem Hosp, Dept Surg Oncol, Mumbai, Maharashtra, India
[11] Univ Calif Davis, Dept Orthopaed Surg, Sacramento, CA 95817 USA
[12] McGill Univ, Dept Surg, Montreal, PQ, Canada
[13] Hosp Valle De Hebron, Dept Orthopaed Surg, Barcelona, Catalunya, Spain
[14] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[15] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源
BMJ OPEN | 2019年 / 9卷 / 09期
关键词
surveillance; soft tissue sarcoma; study protocol; randomised controlled trial; pilot study; FOLLOW-UP; CANCER-PATIENTS; TISSUE; STRATEGIES; SARCOMA; RESECTION; SURVIVAL; COSTS;
D O I
10.1136/bmjopen-2019-029054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Following the treatment of patients with soft tissue sarcomas (STS) that are not metastatic at presentation, the high risk for local and systemic disease recurrence necessitates post-treatment surveillance. Systemic recurrence is most often detected in the lungs. The most appropriate surveillance frequency and modality remain unknown and, as such, clinical practice is highly varied. We plan to assess the feasibility of conducting a multi-centre randomised controlled trial (RCT) that will evaluate the effect on overall 5-year survival of two different surveillance frequencies and imaging modalities in patients with STS who undergo surgical excision with curative intent. Methods and analysis The Surveillance After Extremity Tumor Surgery trial will be a multi-centre 2x2 factorial RCT. Patients with non-metastatic primary Grade II or III STS treated with excision will be allocated to one of four treatment arms(1): chest radiograph (CXR) every 3 months for 2 years(2); CXR every 6 months for 2 years(3); chest CT every 3 months for 2 years or(4) chest CT every 6 months for 2years. The primary outcome of the pilot study is the feasibility of a definitive RCT based on a combination of feasibility endpoints. Secondary outcomes for the pilot study include the primary outcome of the definitive trial (overall survival), patient-reported outcomes on anxiety, satisfaction and quality of life, local recurrence-free survival, metastasis-free survival, treatment-related complications and net healthcare costs related to surveillance. Ethics and dissemination This trial received provisional ethics approval from the McMaster/Hamilton Health Sciences Research Ethics Board on 7 August 2019 (Project number 7562). Final ethics approval will be obtained prior to commencing patient recruitment. Once feasibility has been established and the definitive protocol is finalised, the study will transition to the definitive study.
引用
收藏
页数:10
相关论文
共 34 条
  • [1] [Anonymous], 2015, BONE JOINT RES, V4, P154
  • [2] [Anonymous], 2014, CANC CELL
  • [3] Bozzo AGM, 2018, OPEN SCI FRAMEWORK
  • [4] Current concepts - Computed tomography - An increasing source of radiation exposure
    Brenner, David J.
    Hall, Eric J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) : 2277 - 2284
  • [5] Dalla-Favera R., 2014, CANCER CELL, V25, pe131, DOI DOI 10.1093/annonc/mdu254
  • [6] American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
    Ellis, Lee M.
    Bernstein, David S.
    Voest, Emile E.
    Berlin, Jordan D.
    Sargent, Daniel
    Cortazar, Patricia
    Garrett-Mayer, Elizabeth
    Herbst, Roy S.
    Lilenbaum, Rogerio C.
    Sima, Camelia
    Venook, Alan P.
    Gonen, Mithat
    Schilsky, Richard L.
    Meropol, Neal J.
    Schnipper, Lowell E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1277 - +
  • [7] Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?
    Freidlin, Boris
    Korn, Edward L.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (09):
  • [8] DEVELOPMENT AND TREATMENT OF PULMONARY METASTASES IN ADULT PATIENTS WITH EXTREMITY SOFT-TISSUE SARCOMA
    GADD, MA
    CASPER, ES
    WOODRUFF, JM
    MCCORMACK, PM
    BRENNAN, MF
    [J]. ANNALS OF SURGERY, 1993, 218 (06) : 705 - 712
  • [9] Gerrand C H, 2007, Sarcoma, V2007, P34128, DOI 10.1155/2007/34128
  • [10] Goel A, 2004, INT J ONCOL, V25, P429